KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Other Operating Expenses (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Other Operating Expenses for 17 consecutive years, with $6.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 8.41% to $6.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $21.6 billion, a 41.66% decrease, with the full-year FY2025 number at $21.6 billion, down 41.66% from a year prior.
  • Other Operating Expenses was $6.3 billion for Q4 2025 at Bristol Myers Squibb, up from $4.8 billion in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $18.3 billion in Q1 2024 to a low of $4.4 billion in Q1 2025.
  • A 5-year average of $6.0 billion and a median of $5.3 billion in 2021 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: surged 308.54% in 2024, then tumbled 76.04% in 2025.
  • Bristol Myers Squibb's Other Operating Expenses stood at $5.3 billion in 2021, then dropped by 9.21% to $4.8 billion in 2022, then rose by 10.08% to $5.3 billion in 2023, then skyrocketed by 30.24% to $6.8 billion in 2024, then fell by 8.41% to $6.3 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Other Operating Expenses are $6.3 billion (Q4 2025), $4.8 billion (Q3 2025), and $6.2 billion (Q2 2025).